Intrathecal @entity1772 for management of XXXX : multicenter trial.

@entity1 @entity410 @entity390 @entity508 @entity391 @entity2147 @entity2421 @entity1772 @entity306
Intrathecal @entity1772 infusion has demonstrated effectiveness in decreasing @entity508 of spinal origin. Oral antispasticity medication is minimally effective or not well tolerated in @entity306 . This study assessed the effectiveness of intrathecal @entity1772 in reducing @entity508 in @entity306 . Candidates were screened by randomized, double-blind, intrathecal injections of @entity1772 and placebo. Responders were defined as those who experienced an average reduction of 1.0 in the lower extremities on the Ashworth Scale for @entity508 . Responders received intrathecal @entity1772 via the SynchroMed System and were followed for up to 43 months. Fifty-one @entity1 completed screening and 44 entered open-label trials. Lower-extremity @entity508 decreased from an average baseline score of 3.64 to 1.90 at 39 months. A decrease in upper extremity @entity508 was evidenced over the same study period. Forty-two @entity1 reported adverse events. Most common reports were @entity2421 , @entity410 (no new onset), @entity2147 , and @entity390 or @entity391 . Fifty-nine percent of the @entity1 experienced procedural or system-related events. Spasticity in @entity1 with @entity306 can be treated effectively by continuous intrathecal @entity1772 . Adverse events, although common, were manageable.
